This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Today's Health Winners and Losers

Shares of I-Flow (IFLO) were among the worst-performing health-related stocks Tuesday, slumping 15% after the maker of infusion systems posted fourth-quarter results that missed expectations.

The company reported a loss of $5.3 million, or 23 cents a share, on sales of $26.9 million. The results included stock-based compensation costs of $6.1 million. Analysts polled by Thomson First Call expected break-even earnings, including stock-based compensation costs, on sales of $28.1 million. A year earlier, the company posted a loss of $12.3 million, or 56 cents a share, on sales of $21.1 million.

The company's recent sales results were hurt by a shortage of 5-flourouracil, a widely used chemotherapy drug. The company said the shortage lowered fourth-quarter sales by about $1.9 million. "Because the market availability of 5-FU is not expected to return to normal for several months, we anticipate a comparable impact in the first quarter of 2006," the company said. Shares were trading down $2.49 to $13.81.

United Therapeutics (UTHR - Get Report) fell 8% after the drugmaker posted fourth-quarter results that were well below forecasts. The company earned $29.4 million, or $1.14 a share, on sales of $29.6 million. Excluding a $17.5 million tax benefit, the company earned $11.9 million, or 46 cents a share. Analysts expected earnings of 66 cents a share and sales of $36.9 million. During the year-ago quarter, the company earned $6.9 million, or 28 cents a share, on sales of $21.6 million. Shares were trading down $5.28 to $61.74.

Shares of Triad Hospitals (TRI - Get Report) rose 4% after the hospital operator posted better-than-expected fourth-quarter earnings. The company reported earnings from continuing operations of $59 million, or 68 cents a share, on sales of $1.27 billion. Analysts expected earnings of 66 cents a share and sales of $1.27 billion. A year earlier, the company earned $49.4 million, or 64 cents a share, on sales of $1.08 billion.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ALNY $117.84 0.00%
BMY $67.48 0.00%
NVAX $10.88 0.00%
MRK $57.67 0.00%
NVS $99.80 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs